Lugano, 4 December 2025 – The ESMO Immuno-Oncology Congress 2025 will take place from 10–12 December in London, UK, bringing together specialists in cancer immunotherapy to present and discuss research in this promising field, spanning all areas from basic and translational science to the latest clinical developments. A virtual attendance option will also be available.
The scientific programme will cover key developments in immuno-oncology, including:
-
Combined immunotherapy approaches – ESMO Immuno-Oncology Award recipient Ignacio Melero, (Universidad de Navarra and University of Oxford) will examine novel synergistic strategies and their potential to sustain the continued progress of immunotherapy (Award Keynote lecture).
-
AI in cancer immunotherapy – Sine Reker Hadrup (Technical University of Denmark) will explore how artificial intelligence is advancing the development of immunotherapies (Keynote Lecture).
-
Innovative strategies across cancers and stages – From tumor microenvironment insights and emerging therapeutic targets to mechanisms of resistance and the role of residual immune activity in cancer relapse. (Session).
-
Therapeutic advances – Covering checkpoint inhibition and vaccines in melanoma, emerging cellular and protein-based therapies, updates from ongoing clinical studies, insights into treatment responses and combination approaches (Session).
The results of the studies presented at the congress will be published online as a supplement to IOTECH.
Notes to editors
Please make sure to use the official name of the meeting in your reports: ESMO Immuno-Oncology Congress 2025 and the official congress hashtag #ESMOImmuno25. X, LinkedIn, Bluesky, Instagram, Facebook, YouTube.
Press accreditation
ESMO welcomes press representatives working for recognised press outlets interested in obtaining information and reporting on cancer issues, upon presentation of a letter of assignment and a valid press card. Press representatives are required to observe and abide by the ESMO Policy on Press Activities and the embargo schedule for the ESMO Immuno-Oncology Congress 2025. To apply for press accreditation, please fill out the form available here.
Third Parties Media registration
Third Parties Media representatives and Filming Crews not eligible as press must abide by the ESMO Policy on Media Activities Organised by Third Parties and can request a Third Parties Media badge through registration@esmo.org (Cc media@esmo.org).
About the European Society for Medical Oncology (ESMO)
Representing over 45,000 members, ESMO is a reference for oncology education and information. Driven by a shared determination to secure the best possible outcomes for patients, ESMO is committed to standing by those who care about cancer through addressing the diverse needs of #ONEoncologycommunity, offering #educationforLIFE, and advocating for #accessiblecancerCARE. www.esmo.org
Further information
ESMO Press Office
press@esmo.org